Information Provided By:
Fly News Breaks for January 28, 2020
Jan 28, 2020 | 07:58 EDT
Goldman Sachs analyst Paul Choi raised his price target for Acceleron Pharma to $81 from $47 after the Phase 2 study of sotatercept in pulmonary arterial hypertension achieved both its primary and key secondary endpoints. The analyst, who awaits more detailed data at an upcoming medical conference, reiterates a Neutral rating on Acceleron shares following the "impressive" results.
News For XLRN From the Last 2 Days
There are no results for your query XLRN